PTC Therapeutics Stock News

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $1.53 per share a year ago.

The biotech inked a lucrative royalty deal extension. Its counterparty is -- fittingly -- Royalty Pharma.

PTC Therapeutics shares PTCT, -0.53% jumped 12% premarket on Thursday after the company announced a deal with Royalty Pharma PLC RPRX, -3.58% to monetize up to $1.5 billion of the royalty stream for t

SOUTH PLAINFIELD, N.J. , Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 finan

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price incre

PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination request for the negative CHMP opinion on Translarna.

Drugmaker PTC Therapeutics said on Thursday it plans to cut workforce, which would impact about 25% of the organization, as it aims to reduce its yearly operating expenses.

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc

PTC Therapeutics (PTCT) plunges on negative opinion from the Committee for Medicinal Products for Human Use for conditional marketing and full marketing authorization of Translarna (ataluren) to treat

European regulators voted against fully approving a muscular dystrophy treatment from PTC Therapeutics, and PTC stock crashed Friday.

PTC Therapeutics (NASDAQ:PTCT) stock sank in Friday premarket trading after the European Medicines Agency (EMA) turned down full market authorization for Translarna, its key treatment for Duchenne mu

Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it.

PTC Therapeutics, Inc. lacks solid margins and revenue streams, increasing investment risks. The company focuses on developing medicines for rare disorders, but a failed drug test caused stock price t

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Ron Aldridge - Senior Director, Investor Relations Matthew Klein - Chief Executive

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics c